Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suvorexant for insomnia after alcohol detoxification
ACTRN12625001226493Phase 2Not yet recruiting
- Sponsor
- Eastern Health
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of suvorexant in Insomnia and alcohol use disorder (AUD), sponsored by Eastern Health. Primary endpoint: Feasibility. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
suvorexant
03
Conditions
Insomniaalcohol use disorder (AUD)
Beyond the preview
Go deeper on ACTRN12625001226493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001226493.